Navarro Pérez, DavidTardaguila García, AroaGarcía Oreja, SaraÁlvaro Afonso, Francisco JavierLópez Moral, MateoLázaro Martínez, José Luis2025-03-242025-03-242025-01-09Navarro-Pérez, David, et al. «Treatment of Onychomycosis and the Drug–Drug Interactions in Patients with Diabetes Mellitus and Diabetic Foot Syndrome: A Systematic Review». Infectious Disease Reports, vol. 17, n.º 1, Multidisciplinary Digital Publishing Institute (MDPI), 2025, https://doi.org/10.3390/IDR17010004.2036-744910.3390/idr17010004https://hdl.handle.net/20.500.14352/118915Background: This systematic review reports on treatments for onychomycosis in patients with diabetes and the drug interactions with other drugs in regard to the complicated diabetic patient profile. Methods: The recommendations in the preferred reporting items for systematic reviews and meta-analysis (PRISMA) checklist were applied and the included studies were evaluated using the Consolidated Standards of Reporting Trials (CONSORT) statement and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Searches were conducted in November 2023, using the PubMed (Medline), Scopus, Cochrane Library, and Web of Science databases; studies on antifungal treatments for onychomycosis in patients with diabetes were included. Two authors performed the study selection and data extraction, and any discrepancies between the two reviewers were resolved through discussions with a third reviewer. This review was registered in PROSPERO (CRD42023442107). Results: The systematic review included 10 studies that met the selection criteria. Mycological cures for mild to moderate onychomycosis were: Ageratina pichinchensis (8.6%), 8% ciclopirox (8.6% 24 weeks and 54.3% 48 weeks), 10% efinaconazole (56.5–58.33%), terbinafine (73–76.6%), itraconazole (88.2%), and laser therapy (43.8%). No serious adverse effects or drug interactions were observed because patients with major complications, such as peripheral vascular disease, diabetic neuropathy, liver and renal dysfunction, poorly controlled diabetes, and severe onychomycosis, were excluded. Conclusions: The antifungal treatments described in the included studies are safe for patients with well-controlled diabetes, but there are currently no studies involving patients with diabetes and multiple complications, such as diabetic foot syndrome or severe onychomycosis. Thus, further research is needed in terms of this patient profile.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://doi.org/10.3390/idr17010004https://www.mdpi.com/2036-7449/17/1/4open access616.718.7/.9onychomycosisdiabetesdiabetic footdrug interactionantifungalPodología3299 Otras Especialidades Médicas